BioAtla, Inc. (BCAB) stock
BCABOTCBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.31−0.05 (-3.68%)
Close on Oct 19, 2026Market cap $2.18MP/E –Yield –
BioAtla ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
BioAtla's ebitda for the twelve months ending Jun 30, 2026 was -$31.93M. For fiscal 2025 it was -$58.93M. The highest annual figure on record is -$27.41M in fiscal 2019.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$58.93M | – |
| FY2024 | Dec 31, 2024 | -$73.02M | – |
| FY2023 | Dec 31, 2023 | -$128.47M | – |
| FY2022 | Dec 31, 2022 | -$106.94M | – |
| FY2021 | Dec 31, 2021 | -$95.11M | – |
| FY2020 | Dec 31, 2020 | -$29.09M | – |
| FY2019 | Dec 31, 2019 | -$27.41M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $227.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$9.19M | – |
| Q4 FY2025 | Dec 31, 2025 | -$9.24M | – |
| Q3 FY2025 | Sep 30, 2025 | -$13.73M | – |
| Q2 FY2025 | Jun 30, 2025 | -$18.53M | – |
| Q1 FY2025 | Mar 31, 2025 | -$17.43M | – |
| Q4 FY2024 | Dec 31, 2024 | -$16.02M | – |
| Q3 FY2024 | Sep 30, 2024 | -$11.04M | – |
| Q2 FY2024 | Jun 30, 2024 | -$21.74M | – |
| Q1 FY2024 | Mar 31, 2024 | -$24.22M | – |
| Q4 FY2023 | Dec 31, 2023 | -$28.17M | – |
| Q3 FY2023 | Sep 30, 2023 | -$34.75M | – |
| Q2 FY2023 | Jun 30, 2023 | -$36.91M | – |
| Q1 FY2023 | Mar 31, 2023 | -$28.64M | – |
| Q4 FY2022 | Dec 31, 2022 | -$28.26M | – |
| Q3 FY2022 | Sep 30, 2022 | -$25.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$28.77M | – |
| Q1 FY2022 | Mar 31, 2022 | -$24.03M | – |
| Q4 FY2021 | Dec 31, 2021 | -$23.17M | – |
| Q3 FY2021 | Sep 30, 2021 | -$23.32M | – |
| Q2 FY2021 | Jun 30, 2021 | -$30.13M | – |
| Q1 FY2021 | Mar 31, 2021 | -$18.49M | – |
| Q4 FY2020 | Dec 31, 2020 | -$16.16M | – |
| Q3 FY2020 | Sep 30, 2020 | -$7.73M | – |
| Q2 FY2020 | Jun 30, 2020 | -$4.31M | – |
| Q1 FY2020 | Mar 31, 2020 | -$893.00K | – |
See a number that looks wrong?